Navigation Links
EPA should pursue cumulative risk assessment of phthalates and other chemicals
Date:12/18/2008

WASHINGTON -- The U.S. Environmental Protection Agency should examine whether combined exposures to chemicals known as phthalates could cause adverse health effects in humans, says a new report from the National Research Council. In addition, this analysis, called a cumulative risk assessment, should consider other chemicals that could potentially cause the same health effects as phthalates, instead of focusing on chemicals that are similar in structure, which is EPA's current practice. Furthermore, EPA should consider using the recommended approach for future cumulative risk assessments on other kinds of chemicals.

Phthalates are used in a wide variety of consumer products, such as cosmetics, medical devices, children's toys, and building materials. In light of concerns, the European Union and the United States have passed legislation that restricts the concentrations of several phthalates in children's toys, and the European Union has also banned several phthalates from cosmetics. EPA asked the Research Council to recommend whether it should conduct a cumulative risk assessment for phthalates, and if so, how it should be framed. Accordingly, the National Research Council report is not a comprehensive profile on the health effects of phthalates.

Recent animal studies have increased understanding of the potential risks from phthalates, although few human studies on the health effects of phthalates are available, said the committee that wrote the report. To decide whether a cumulative risk assessment is warranted, two factors needed to be determined: whether humans are exposed to multiple phthalates at any given time, and whether sufficient evidence exists linking exposures to similar adverse health effects. The committee established that recent studies have shown widespread human exposure to multiple phthalates, including in utero exposure.

Then, the committee reviewed animal research and found that exposure to various phthalates in lab animals produced similar health outcomes, including a range of effects on the development of the male reproductive system. The most notable effects in male rats are infertility, undescended testes, malformation of the penis, and other reproductive tract malformations. However, the severity of effects differs among phthalates; some exhibit less severe or no effects. Furthermore, the age of the animals at the time of exposure is critical to the severity of the effects. For example, the fetus is most sensitive. Given that multiple human exposures to phthalates occur and that research shows exposure to different phthalates leads to similar outcomes in lab animals, a cumulative risk assessment is called for, the committee said.

The animal studies reviewed by the committee also indicated that some phthalates reduce testosterone concentrations. Depending on when this drop occurs, it can cause a variety of effects in animals that are critical for male reproductive development. Other chemicals known as antiandrogens, which prevent or inhibit male hormones from working, can produce similar effects in lab animals. The committee recommended that phthalates and other chemicals that affect male reproductive development in animals, including antiandrogens, be considered in the cumulative risk assessment. A focus solely on phthalates to the exclusion of other chemicals would be artificial and could seriously underestimate risk, the committee emphasized.

Currently when conducting cumulative risk assessments, EPA often considers only chemicals that are structurally related, on the assumption that they have the same chain of reactions that lead to a final health outcome. That practice ignores how exposures to different chemicals may result in the same health effects. The conceptual approach taken for phthalates -- to consider chemicals that cause similar health effects -- should also be applied when completing any cumulative risk assessment, the committee said. For instance, EPA could evaluate the risk of combined exposures to lead, methylmercury, and polychlorinated biphenyls because all contribute to cognitive deficits consistent with IQ reduction in children.

In addition, further research should be conducted to allow greater refinement of the cumulative risk assessment associated with phthalates and reduce uncertainty associated with such an assessment, the report says. Moving beyond the constraints of grouping chemicals based on structural similarity may appear challenging, but it is feasible to evaluate the multiplicity of human exposures. It also directly reflects EPA's mission to protect human health, the committee noted. Such a shift in approach would entail substantial efforts by EPA, such as defining and setting priorities among the most prominent adverse health effects. However, a focus on similar outcomes facilitates the process by identifying the groups of chemicals that should be included.


'/>"/>

Contact: Jennifer Walsh
news@nas.edu
202-334-2138
National Academy of Sciences
Source:Eurekalert

Related medicine news :

1. Stakeholders and public should use 20 specific health indicators
2. Patient consent forms should educate not intimidate
3. Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care
4. Regence Supports Meaningful Health Reforms; Unveils Poll Saying Nations Economic Woes Shouldnt Delay Reforms
5. AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next
6. People who want access to the NHS should behave more responsibly, says expert
7. Parents of new babies should be considered for a whooping cough booster, say experts
8. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Give FDA Authority Over Tobacco Products
9. Why women should eat less, move more and consider wearing transdermal HRT patches during menopause
10. States Should Fund Quit-Smoking Treatments: Experts
11. CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... 22, 2017 , ... Ecommerce sales have grown every year since the 1990’s, ... The consequences of rapid innovation and growth are often neglected in the name ... every business and individual’s job to give something back to the planet that provides ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... LAKE CITY, Utah (PRWEB) , ... April 21, ... ... provider of wilderness therapy treatment for adolescents and young adults, has kicked off ... April 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for ...
(Date:4/21/2017)... ... 2017 , ... The Patient Advocacy Community of The Beryl Institute presented Eve ... Ravich Patient Advocacy Award in recognition of her extraordinary contributions to the field ... at The Beryl Institute’s annual Patient Experience Conference on March 20 in ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness ... wish to overcome their mental health struggles. The Alive team uses advanced behavioral ... “Our approach in dealing with a mental health struggle is based on 10 ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
Breaking Medicine Technology: